FI896046A0 - Foerfarande foer behandling av endotoxisk shock hos daeggdjur. - Google Patents

Foerfarande foer behandling av endotoxisk shock hos daeggdjur.

Info

Publication number
FI896046A0
FI896046A0 FI896046A FI896046A FI896046A0 FI 896046 A0 FI896046 A0 FI 896046A0 FI 896046 A FI896046 A FI 896046A FI 896046 A FI896046 A FI 896046A FI 896046 A0 FI896046 A0 FI 896046A0
Authority
FI
Finland
Prior art keywords
shock
endotoxisk
daeggdjur
hos
foerfarande foer
Prior art date
Application number
FI896046A
Other languages
English (en)
Inventor
Allan Wissner
Suresh S Kerwar
Constance Kohler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI896046A0 publication Critical patent/FI896046A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measurement Of Force In General (AREA)
  • Thermistors And Varistors (AREA)
  • Surgical Instruments (AREA)
  • Percussive Tools And Related Accessories (AREA)
  • Disintegrating Or Milling (AREA)
FI896046A 1988-12-19 1989-12-18 Foerfarande foer behandling av endotoxisk shock hos daeggdjur. FI896046A0 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28620188A 1988-12-19 1988-12-19

Publications (1)

Publication Number Publication Date
FI896046A0 true FI896046A0 (fi) 1989-12-18

Family

ID=23097534

Family Applications (1)

Application Number Title Priority Date Filing Date
FI896046A FI896046A0 (fi) 1988-12-19 1989-12-18 Foerfarande foer behandling av endotoxisk shock hos daeggdjur.

Country Status (18)

Country Link
US (1) US5124147A (fi)
EP (1) EP0374510B1 (fi)
JP (1) JP2931344B2 (fi)
KR (1) KR0148680B1 (fi)
AT (1) ATE147634T1 (fi)
AU (1) AU624457B2 (fi)
CA (1) CA2005670A1 (fi)
DE (1) DE68927671T2 (fi)
DK (1) DK641889A (fi)
ES (1) ES2096553T3 (fi)
FI (1) FI896046A0 (fi)
GR (1) GR3022969T3 (fi)
IL (1) IL92471A (fi)
NZ (1) NZ231725A (fi)
PH (1) PH31376A (fi)
PT (1) PT92596B (fi)
SG (1) SG43205A1 (fi)
ZA (1) ZA899685B (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231091A (en) * 1988-12-19 1993-07-27 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US5147864A (en) * 1988-12-19 1992-09-15 American Cyanamid Company Bis-arylphosphate ester antagonists of platelet activating factor
US4983592A (en) * 1988-12-19 1991-01-08 American Cyanamid Co. Bis-arylphosphate ester antagonists of platelet activating factor
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
EP0739488A1 (en) * 1994-01-14 1996-10-30 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
WO1995024501A1 (en) 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
ES2179929T3 (es) * 1995-01-23 2003-02-01 Xenotech Inc Procedimiento que trata de inhibir la osteolisis y las metastasis.
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CA2590164A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CA2911000A1 (en) 2006-04-05 2007-10-18 Min W. Wan Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148879A (en) * 1977-12-23 1979-04-10 Nelson Research & Development Company Inhibition of platelet aggregation with selected phosphonic and phosphinic acid esters

Also Published As

Publication number Publication date
KR0148680B1 (ko) 1998-08-17
AU4688589A (en) 1990-06-21
PT92596A (pt) 1990-06-29
ES2096553T3 (es) 1997-03-16
DE68927671T2 (de) 1997-05-07
KR900009097A (ko) 1990-07-02
DK641889D0 (da) 1989-12-18
IL92471A (en) 1995-06-29
NZ231725A (en) 1992-12-23
SG43205A1 (en) 1997-10-17
IL92471A0 (en) 1990-08-31
EP0374510B1 (en) 1997-01-15
GR3022969T3 (en) 1997-06-30
PT92596B (pt) 1996-06-28
AU624457B2 (en) 1992-06-11
JP2931344B2 (ja) 1999-08-09
DE68927671D1 (de) 1997-02-27
US5124147A (en) 1992-06-23
JPH02212435A (ja) 1990-08-23
ZA899685B (en) 1990-09-26
PH31376A (en) 1998-10-29
DK641889A (da) 1990-06-20
CA2005670A1 (en) 1990-06-19
ATE147634T1 (de) 1997-02-15
EP0374510A1 (en) 1990-06-27

Similar Documents

Publication Publication Date Title
FI896046A0 (fi) Foerfarande foer behandling av endotoxisk shock hos daeggdjur.
NO940219D0 (no) Rekombinante antistoffer for human terapi
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
DE69324596T2 (de) Rekombinante humanisierte anti-cytomegalovirus antikörper
ES2121907T3 (es) Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE69319662T2 (de) Monoklonale Antikörper gegen GP130-Protein
DE3587275D1 (de) Durch rehydratation bindbares aluminiumoxid.
DE3482905D1 (de) Monoklonale antikoerper gegen lungenkrebs des "nicht-kleine-zellen"-typs.
DK149990A (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
DE3885355D1 (de) Monoklonale Antikörper.
DE68911653D1 (de) Antagonist für Interleukin-5 zur Verhütung oder Verminderung von Eosinophilie.
DK717888D0 (da) Monoklonale antistoffer
FI885169A0 (fi) Monoklonaalinen vasta-aine, joka tunnistaa N-asetyylineuramiinihapon -järjestyksessä, sen käyttö ja sitä tuottava hybridooma
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
IT1163911B (it) Resina per lenti di elevata rifrattivita' e lenti prodotte con la resina stessa
IT9041599A0 (it) Anticorpo monoclonale che inibisce l'azione biologica del fattore piastrinico 4
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
NO924137D0 (no) Monoklonale anti-igm-antistoffer, deres fremstilling og anvendelse, og hybridomas for fremstilling av de samme
DE69126302D1 (de) Monoklonaler antikörper gegen herzglykosid und dessen verwendung
ITPD910230A0 (it) Nuovi anticorpi monoclonali specifici per il fattore neurofonico ciliare (cntf) umano ricombinante
DE3890354T1 (de) Synthetisches polypeptid mit grippevirus-antigenreaktivitaet
IT1194260B (it) Linfochine e anticorpi monoclonali umani

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: AMERICAN CYANAMID COMPANY